Target product profile of a molecular drug-susceptibility test for use in microscopy centers

Journal of Infectious Diseases

Volumn 211, Issue , 2015, Pages S39-S49

  Denkinger, Claudia M ^a,d   Dolinger, David ^a   Schito, Marco ^e   Wells, William ^f,n   Cobelens, Frank ^i,j   Pai, Madhukar ^k,l   Zignol, Matteo ^b   Cirillo, Daniela Maria ^m   Alland, David ^g   Casenghi, Martina ^c   Gallarda, Jim ^h   Boehme, Catharina C ^a   Perkins, Mark D ^a  

^a Malaria Fever Program   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^f TB Alliance   (United States)

^g RUTGERS UNIVERSITY   (United States)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

ⁱ KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^j AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^k MCGILL UNIVERSITY   (Canada)

^l MCGILL UNIVERSITY   (Canada)

^m SAN RAFFAELE HOSPITAL   (Italy)

ⁿ UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

more..

Author keywords

Diagnostics; Molecular testing; Point of care; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; CALIBRATION; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEALTH CARE FACILITY; HEALTH CARE NEED; MICROSCOPY CENTER; MOLECULAR DRUG SUSCEPTIBILITY TEST; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; QUALITY CONTROL; TARGET PRODUCT PROFILE; TUBERCULOSIS; DIAGNOSTIC TEST; HUMAN; MICROBIAL SENSITIVITY TEST; MOLECULAR DIAGNOSIS; PROCEDURES; STANDARDS; TIME FACTOR;

ANTITUBERCULAR AGENTS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; QUALITY CONTROL; TIME FACTORS; TUBERCULOSIS;

EID: 84930007214     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu682     Document Type: Article

References (59)

1. World Health Organization (WHO). Global tuberculosis report 2011. Geneva: WHO, 2011.
2. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO, 2014.
3. Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child 2003; 88:1106-11.
4. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-505.
5. World Health Organization (WHO). Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO, 2014.
6. UNITAID. Tuberculosis: diagnostics technology and market landscape. 3rd ed. Geneva: World Health Organization, 2014.
7. Niemz A, Boyle DS. Nucleic acid testing for tuberculosis at the point-ofcare in high-burden countries. Expert Rev Mol Diagn 2012; 12:687-701.
8. Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J 2012; 102:805-7.
9. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 2012; 9:e1001306.
10. Wells WA, Konduri N, Chen C, et al. Tuberculosis regimen change in high-burden countries. Int J Tuberc Lung Dis 2010; 14:1538-47.
11. Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013; 13:449-58.
12. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacinbased regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371:1577-87.
13. TB Alliance. Clinical development portfolio. http://www.tballiance.org/ portfolio/. Accessed 29 September 2014.
14. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986-93.
15. Pai M. Tuberculosis diagnostics: test developers' FAQs. Int J Tuberc Lung Dis 2013; 17:570-1.
16. Qin ZZ, Pai M, van Gemert W, Sahu S, Ghiasi M, Creswell J. How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? Eur Resp J 2014; doi:10.1183/09031936.00147714.
17. Consortium TBDMA. Market assessment of tuberculosis diagnostics in Brazil in 2012. PLoS One 2014; 9:e104105.
18. Dowdy DW, Hoog AV, Shah M, Cobelens F. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis. Int J Tuberc Lung Dis 2014; 18:647-54.
19. Sun AY, Pai M, Salje H, Satyanarayana S, Deo S, Dowdy DW. Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia. Am J Epidemiol 2013; 178:1740-9.
20. Salje H, Andrews JR, Deo S, et al. The importance of implementation strategy in scaling up XpertMTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model. PLoS Med 2014; 11:e1001674.
21. Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur Respir J 2013; 42:544-7.
22. Kik SV, Denkinger CM, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J 2014; 43:1793-6.
23. World Health Organization (WHO). High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: WHO, 2014.
24. World Health Organization (WHO). Global tuberculosis report 2014. Geneva: WHO, 2014.
25. Denkinger CM, Kik SV, Pai M. Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries. Expert Rev Mol Diagn 2013; 13:763-7.
26. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006; 444(suppl 1):49-57.
27. Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME. Which new diagnostics for tuberculosis, and when? J Infect Dis 2012; 205(suppl 2):S191-8.
28. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010; 48:2495-501.
29. World Health Organization (WHO). Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Geneva: WHO, 2013.
30. Ando H, Mitarai S, Kondo Y, et al. Pyrazinamide resistance in multidrug- resistant Mycobacterium tuberculosis isolates in Japan. Clin Microbiol Infect 2010; 16:1164-8.
31. Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol 2010; 10:223.
32. Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis 2012; 16:203-5.
33. Denkinger CM, Pai M, Dowdy DW. Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis? PLoS One 2014; 9:e84197.
34. Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med 2013; 5:180ra49.
35. Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One 2011; 6:e22927.
36. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012; 16:1005-14.
37. Barnard M, Warren R, Gey Van Pittius N, et al. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012; 186:1298-305.
38. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32:1165-74.
39. Feng Y, Liu S, Wang Q, et al. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS One 2013; 8:e55292.
40. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47:1767-72.
41. Said HM, Kock MM, Ismail NA, et al. Evaluation of the GenoType(R) MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2012; 16:104-9.
42. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people withmultidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380:1406-17.
43. Horne DJ, Pinto LM, Arentz M, et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol 2013; 51:393-401.
44. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48:229-37.
45. Claassens MM, du Toit E, Dunbar R, et al. Tuberculosis patients in primary care do not start treatment. What role do health system delays play? Int J Tuberc Lung Dis 2013; 17:603-7.
46. Sreeramareddy CT, Kishore PV, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis 2009; 9:91.
47. World Health Organization (WHO). Tuberculosis laboratory biosafety manual. Geneva: WHO, 2012.
48. Banoo S, Bell D, Bossuyt P, et al. Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol 2010; 8: S17-29.
49. Parsons LM, Somoskovi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011; 24:314-50.
50. Denkinger CM, Grenier J, Stratis AK, Akkihal A, Pant-Pai N, Pai M. Mobile health to improve tuberculosis care and control: a call worth making. Int J Tuberc Lung Dis 2013; 17:719-27.
51. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 1:CD009593.
52. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42:156-68.
53. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-80.
54. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with monoresistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6:e1000150.
55. Langley I, Lin HH, Egwaga S, et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Global Health 2014; 2:e581-91.
56. Denkinger CM, Grenier J, Minion J, Pai M. Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics. J Clin Microbiol 2012; 50:2455-61.
57. Raizada N, Sachdeva KS, Sreenivas A, et al. Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India. PLoS One 2014; 9:e89301.
58. Stucki D, Gagneux S. Single nucleotide polymorphisms in Mycobacterium tuberculosis and the need for a curated database. Tuberculosis (Edinb) 2013; 93:30-9.
59. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6:e2.